Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Exelixis partners early-stage PI3K-delta program with Merck

Executive Summary

Exelixis Inc. (focusing on small-molecule cancer candidates) has licensed Merck & Co. Inc. exclusive global rights to develop and market compounds from its research program on phosphoinositide-3 kinase delta (PI3K-delta) inhibitors. The deal includes preclinical XL499 and other candidates.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R+D and Marketing-Licensing

Related Companies